Overview
QNCX market data
Price History
QNCX price chart · 1M
- O
- 31.32
- H
- 32.23
- L
- 31.22
- C
- 32.23
- Vol
- 670.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $31.32
- Previous Close
- $31.75
- Day High
- $32.23
- Day Low
- $31.22
- 52 Week High
- $35.41
- 52 Week Low
- $15.79
- 7 Day Return
- -2.69%
- 30 Day Return
- +71.44%
- 90 Day Return
- +39.52%
- 1 Year Return
- +32.09%
- Daily Notional Volume
- $21.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$335.27 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.31 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.10 – $910.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $33.6M · P/B 2.73.
Company News
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price TargetBenzinga · Aug 18, 2026, 10:59 AM
8-K filing — Quince Therapeutics, Inc. (QNCX)SEC EDGAR · Aug 17, 2026, 10:01 AM
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) EstimateBenzinga · Aug 14, 2026, 12:19 PM
Quince Therapeutics Says Brigette Roberts Conditionally Appointed As CEO; John Militello Conditionally Appointed As CFOBenzinga · Jul 31, 2026, 8:55 PM
Quince Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $82 price target.Benzinga · Jul 29, 2026, 5:52 PM
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82Benzinga · Jul 29, 2026, 4:23 PM
8-K/A filing — Quince Therapeutics, Inc. (QNCX)SEC EDGAR · Jun 26, 2026, 8:31 PM
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4Benzinga · Jun 24, 2026, 6:50 PM
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4Benzinga · Jun 23, 2026, 4:15 PM